Trial
NCT00667017
RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Texas Southwestern Medical Center
Collaborators
—
Condition
Lymphoma
Intervention
RFT5-dgA immunotoxin
Why stopped
Slow accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-12-14